Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain

References

• Whiteford HA, Ferrari AJ, Degenhardt L, et al. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One 2015;10:e0116820
   PubMed Web of Science ®Google Scholar
• Saha S, Chant D, Welham JJM. A systematic review of the prevalence of schizophrenia. PLoS Med 2005;2:e141
   PubMed Web of Science ®Google Scholar
• Population Reference Bureau. 2010 world population data sheet. http://www.prb.org/pdf10/10wpds_eng.pdf. Accessed May 21, 2017
   Google Scholar
• McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76
   PubMed Web of Science ®Google Scholar
• Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008;102:1-18
   PubMed Web of Science ®Google Scholar
• Ayuso-Mateos JL, Gutierrez-Recacha P, Haro JM, et al. Estimating the prevalence of schizophrenia in Spain using a disease model. Schizophr Res 2006;86:194-201
   PubMed Web of Science ®Google Scholar
• Moreno-Küstner B, Mayoral F, Navas-Campaña D, et al. Prevalence of schizophrenia and related disorders in Malaga (Spain): results using multiple clinical databases. Epidemiol Psychiatr Sci 2016;25:38-48
   PubMed Web of Science ®Google Scholar
• Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M. Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Early Interv Psychiatry 2008;2:178-87
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res 2009;110:1-23
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
   PubMed Web of Science ®Google Scholar
• Haro JM, Altamura C, Corral R, et al. Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study. Schizophr Res 2015;169:234-40
   PubMed Web of Science ®Google Scholar
• Haro JM, Novick D, Perrin E, et al. Symptomatic remission and patient quality of life in an observational study of schizophrenia: is there a relationship? Psychiatry Res 2014;220:163-9
   PubMed Web of Science ®Google Scholar
• Crump CWM, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013;170:324-33
   PubMed Web of Science ®Google Scholar
• Azad MC, Shoesmith WD, Al Mamun M, et al. Cardiovascular diseases among patients with schizophrenia. Asian J Psychiatry 2016;19:28-36
   PubMed Web of Science ®Google Scholar
• Ringen PA, Engh JA, Birkenaes AB, et al. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry 2014;5:137
   PubMed Web of Science ®Google Scholar
• Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11-53
   Google Scholar
• Hughes JR, Hatsukami DK, Mitchell JE, et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993-7
   PubMed Web of Science ®Google Scholar
• Hartz SM, Pato CN, Medeiros H. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014;71:248-54
   PubMed Web of Science ®Google Scholar
• Druss BG, Bradford DW, Rosenheck RA, et al. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 2000;283:506-11
   PubMed Web of Science ®Google Scholar
• Smith DJ, Langan J, McLean G, et al. Schizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional study. BMJ Open 2013;3:pii:e002808
   PubMed Web of Science ®Google Scholar
• Nicholl D, Akhras KS, Diels J, et al. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 2010;26:943-55
   PubMed Web of Science ®Google Scholar
• Baca-Garcia E, Perez-Rodriguez MM, Basurte-Villamor I, et al. Patterns of mental health service utilization in a general hospital and outpatient mental health facilities: analysis of 365,262 psychiatric consultations. Eur Arch Psychiatry Clin Neurosci 2008;258:117-23
   PubMed Web of Science ®Google Scholar
• Gupta S, Isherwood G, Jones K, et al. Productivity loss and resource utilization, and associated indirect and direct costs in individuals providing care for adults with schizophrenia in the EU5. Clinicoecon Outcomes Res 2015;7:593-602
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008;26:149-62
   PubMed Web of Science ®Google Scholar
• Aranda-Reneo I, Oliva-Moreno J, Vilaplana-Prieto C, et al. Informal care of patients with schizophrenia. J Ment Health Policy Econ 2013;16:99-108
   PubMed Web of Science ®Google Scholar
• Oliva-Moreno J, López-Bastida J, Osuna-Guerrero R, et al. The costs of schizophrenia in Spain. Eur J Health Econ 2006;7:182-8
   PubMedGoogle Scholar
• Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109-13
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91
   PubMed Web of Science ®Google Scholar
• Acosta FJ, Bosch E, Sarmiento G, et al. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res 2009;107:213-17
   PubMed Web of Science ®Google Scholar
• Dilla T, Ciudad A, Alvarez M. Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia. Patient Prefer Adherence 2013;7:275-84
   PubMed Web of Science ®Google Scholar
• Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Evaluate Group. 2003. Alkermes announces risperdal consta approved in Spain. http://www.evaluategroup.com/Universal/View.aspx?type=Story&id = 37484. Accessed March 17, 2016
   Google Scholar
• European Medicines Agency. 2011. Xeplion authorization details. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002105/human_med_001424.jsp&mid=WC0b01ac058001d125. Accessed March 17, 2016
   Google Scholar
• Lamb YN, Keating GM. Paliperidone palmitate intramuscular 3-monthly formulation: a review in schizophrenia. Drugs 2016;76:1559-66
   PubMed Web of Science ®Google Scholar
• Gopal S, Vermeulen A, Nandy P, et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Curr Med Res Opin 2015;31:2043-54
   PubMed Web of Science ®Google Scholar
• López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010;11:513-20
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol 2016;19
   PubMed Web of Science ®Google Scholar
• Kim E, Berwaerts J, Turkoz I, et al. Time to schizophrenia relapse in relapse-prevention studies of antipsychotics developed for administration daily, once monthly, and every 3 months. Presented at the 15th International Congress on Schizophrenia Research, Colorado Springs, CO, USA, March 28–April 1, 2015
   Google Scholar
• Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24
   Google Scholar
• National Institute for Health and Clinical Excellence. The NICE guidelines on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. London: NICE; 2010
   Google Scholar
• Organisation for Economic Cooperation and Development. Consumer Price Index. http://stats.oecd.org/Index.aspx?DatasetCode=MEI_PRICES. Accessed March 19, 2016
   Google Scholar
• Osborne RH, Dalton A, Hertel J, et al. Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study. Health Qual Life Outcomes 2012;10:35
   PubMed Web of Science ®Google Scholar
• Tempest M, Sapin C, Beillat M, et al. Cost-effectiveness analysis of aripiprazole once-monthly for the treatment of schizophrenia in the UK. J Ment Health Policy Econ 2015;18:185-200
   PubMed Web of Science ®Google Scholar
• Druais S, Doutriaux A, Cognet M, et al. Cost effectiveness of paliperidone long-acting injectable versus other antipsychotics for the maintenance treatment of schizophrenia in France. Pharmacoeconomics 2016;34:363-91
   PubMed Web of Science ®Google Scholar
• Einarson TR, Maia-Lopes S, Goswami P, et al. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. J Med Econ 2016;19:913-21
   PubMed Web of Science ®Google Scholar
• Mede Herrero A, Saria Santamera A. Hospital indicators by regional communities, 1980–2004. Longitudinal analysis of morbidity indicators and hospital staffing in mental health. Actas Esp Psichiatr 2009;37:82-93
   PubMed Web of Science ®Google Scholar
• Gaviria AM, Franco JG, Aguado V. A non-interventional naturalistic study of the prescription patterns of antipsychotics in patients with schizophrenia from the Spanish province of Tarragona. PLoS One 2015;10:e0139403
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Orefice G, Prinster A, et al. Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy. Neurol Sci 2011;32:287-92
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011;27:713-30
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry 2015;72:830-9
   PubMed Web of Science ®Google Scholar
• Hough D, Gopal S, Vijapurkar U. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116:107-17
   PubMed Web of Science ®Google Scholar
• Fu DJ, Turkoz I, Simonson RB, et al. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry 2015;76:253-62
   PubMed Web of Science ®Google Scholar
• Ravenstijn P, Remmerie B, Savitz A, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study. J Clin Pharmacol 2016;56:330-9
   PubMed Web of Science ®Google Scholar
• Leng D, Chen H, Li G, et al. Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size. Int J Pharm 2014;472:380-5
   PubMed Web of Science ®Google Scholar
• Park EJ, Amatya S, Kim MS, et al. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch Pharm Res 2013;36:651-9
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. 1993. Drug approval package: Betaseron (Chiron Corp.). http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/103471s0000TOC.cfm. Accessed August 2, 2016
   Google Scholar
• Arteaga Duarte C, Guillon P, Fakra E, et al. Three-monthly long-acting formulation of paliperidone palmitate is a dominant treatment option, cost saving while adding QALYs, compared to the one-monthly formulation in the treatment of schizophrenia in France. Poster PRM115. Presented at the ISPOR 19th Annual European Congress, Vienna, Austria, October 29–November 2, 2016. Value Health 2016;19:A378
   Web of Science ®Google Scholar
• De Moor R, Malfait B, Tedouri F, et al. Three-monthly long-acting formulation of paliperidone is a dominant treatment option, cost saving while adding QALYs, compared to the one-monthly formulation in the treatment of schizophrenia in Belgium. Poster PMH28. Presented at the ISPOR 19th Annual European Congress, Vienna, Austria, October 29–November 2, 2016 Value Health 2016;19:A526
   Web of Science ®Google Scholar
• Benson C, Chirila C, Graham J, et al. Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse-prevention study of paliperidone palmitate 3-month formulation. Presented at the ISPOR 20th Annual International Meeting; May 16–20, 2015; Philadelphia, PA; 2015
   Google Scholar
• Benson C, Chirila C, Graham J, et al. PMH27 Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse-prevention study of paliperidone palmitate 3-month formulation. ISPOR 2015;18:A119
   Google Scholar
• Vázquez-Polo FJ, Negrín M, Cabasés JM, et al. An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach. J Ment Health Policy Econ 2005;8:153-65
   PubMed Web of Science ®Google Scholar
• Evensen S, Wisløff T, Lystad JU, et al. Prevalence, employment rate, and cost of schizophrenia in a high-income welfare society: a population-based study using comprehensive health and welfare registers. Schizophr Bull 2016;42:476-83
   PubMed Web of Science ®Google Scholar
• Davidson M, Kapara O, Goldberg S, et al. A nation-wide study on the percentage of schizophrenia and bipolar disorder patients who earn minimum wage or above. Schizophr Bull 2016;42:443-7
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2015. Xeplion® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002105/WC500103317.pdf. Accessed March 19, 2016
   Google Scholar
• European Medicines Agency. 2016. Abilify Maintena® summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002755/WC500156111.pdf. Accessed March 19, 2016
   Google Scholar
• Haro JM, Salvador-Carulla L, Cabasos J, et al. Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. BJP 1998;173:334-40
   Web of Science ®Google Scholar
• Mede A, Sarria A. Hospital indicators by Regional Communities, 1980–2004 (Longitudinal analysis of morbidity indicators and hospital staffing in mental health). Actas Esp Psiquiatr 2009;37:82-93
   PubMed Web of Science ®Google Scholar
• Peiró S, Gómez G, Navarro M, et al. Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain. Description and associated factors. The Psychosp study. Soc Psychiatry Psychiatr Epidemiol 2004;39:507-13
   PubMed Web of Science ®Google Scholar
• Salize HJ, McCabe R, Bullenkamp J, et al. Cost of treatment of schizophrenia in six European countries. Schizophr Res 2009;111:70-7
   PubMed Web of Science ®Google Scholar
• Salvador-Carulla L, Haro JM, Cabasés J, et al. Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in North-East Spain. PSICOST Group. Acta Psychiatr Scand 1999;100:335-43
   PubMed Web of Science ®Google Scholar
• Consejo General de Colegios Oficiales de Farmaceuticos. http://botplusweb.portalfarma.com/botplus.aspx. Accessed December 12, 2016
   Google Scholar
• Diario Oficial de Galicia. https://edog100.xunta.es/dogPublicador/loginPublicador.do;jsessionid=bdhQYSSGzGBpMn6HhNQ9xCy29ZP-qDjCFFyGpY5MsY1PBLMQXlrYW!34097549!-309920421?method=loginPublicadorI
   Google Scholar
• García-Ruiz AJ, Pérez-Costillas L, Montesinos AC, et al. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. Health Econ Rev 2012;2:doi: 10.1186/2191-1991-1182-1188
   PubMedGoogle Scholar
• Quintero J, Oyagüez I, González B, et al. Cost-minimisation analysis of paliperidone palmitate long-acting treatment versus risperidone long-acting treatment for schizophrenia in Spain. Clin Drug Investig 2016;36:479-90
   PubMed Web of Science ®Google Scholar
• Smith PH, Mazure CM, McKee SA. Smoking and mental illness in the U.S. population. Tob Control 2014;23:e147-53
   PubMed Web of Science ®Google Scholar